| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $35.8M | — | -25.7% |
| SG&A Expense | $10.3M | — | +11.3% |
| Operating Income | -$46.1M | — | +19.8% |
| Net Income | -$44.1M | — | +18.8% |
| EPS (Basic) | -$0.23 | — | +37.8% |
| EPS (Diluted) | -$0.23 | — | +37.8% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $175.2M | +8.1% | +80.4% |
| Current Assets | $228.3M | -5.7% | -14.9% |
| Total Assets | $262.9M | -5.3% | -13.2% |
| Current Liabilities | $35.9M | -15.7% | +7.1% |
| Total Liabilities | $58.4M | -11.5% | -1.5% |
| Stockholders' Equity | $204.5M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$46.8M | — | +6.5% |
| Capital Expenditures | $0 | — | -100.0% |
| Investing Cash Flow | $27.1M | — | -72.3% |
| Financing Cash Flow | $32.9M | — | — |
| Free Cash Flow | -$46.8M | — | +6.6% |
| -16.1% |